GRI VS THAR Stock Comparison

Performance

GRI
10/100

GRI returned -91.59% in the last 12 months. Based on SPY's performance of 15.17%, its performance is below average giving it a score of 10 of 100.

THAR
10/100

THAR returned -18.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

GRI
20/100

Out of the last 4 quarters, GRI has had 1 profitable quarters and has increased their profits year over year on 0 of them.

THAR

"Profit" not found for THAR

Volatility

GRI
36/100

GRI has had a lower than average amount of volatility over the last 12 months giving it a score of 36 of 100.

THAR
50/100

THAR has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

Earnings

GRI

"Earnings" not found for GRI

THAR
100/100

THAR has missed earnings 1 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

GRI Bio, Inc. Common Stock Summary

Nasdaq / GRI

Healthcare

Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Tharimmune, Inc. Common Stock Summary

Nasdaq / THAR

Healthcare

Biotechnology

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Power up your portfolio